Supplementary references


77. Hentschel F, Kreis M, Damian M, et al. The clinical utility of structural neuroimaging with MRI for
diagnosis and differential diagnosis of dementia: a memory clinic study. International Journal of

78. Sørensen L, Igel C, Pai A, et al. Differential diagnosis of mild cognitive impairment and
Alzheimer’s disease using structural MRI cortical thickness, hippocampal shape, hippocampal


81. Apostolova LG, Thompson PM, Green AE, et al. 3D comparison of low, intermediate, and
advanced hippocampal atrophy in MCI. Hum Brain Mapp 2010;31(5):786-97.


2007;1097:183.


85. Foster NL, Heidebrink JL, Clark CM, et al. FDG-PET improves accuracy in distinguishing


88. Mielke R, Pietrzyk U, Jacobs A, et al. HMPAO SPET and FDG PET in Alzheimer’s disease and
1994;21(10):1052-60.

with probable Alzheimer’s disease: comparison with fluorine-18-FDG PET. 1994

90. Van Dyck CH, Nygaard HB, Chen K, et al. Effect of AZD0530 on cerebral metabolic decline in
alzheimer disease: a randomized clinical trial. JAMA neurology 2019;76(10):1219-29.

91. Johnson KA, Minoshima S, Bohnen NI, et al. Appropriate use criteria for amyloid PET: a report of
the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the


